Literature DB >> 8411069

Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis.

L V Nicholson1, M A Johnson, K M Bushby, D Gardner-Medwin, A Curtis, I B Ginjaar, J T den Dunnen, J L Welch, T J Butler, E Bakker.   

Abstract

This report is the third part of a trilogy from a multidisciplinary study which was undertaken to investigate gene and protein expression in a large cohort of patients with well defined and diverse clinical phenotypes. The aim of part 3 was to review which of the analytical techniques that we had used would be the most useful for differential diagnosis, and which would provide the most accurate indication of disease severity. Careful clinical appraisal is very important and every DMD patient was correctly diagnosed on this basis. In contrast, half of the sporadic BMD patients and all of the sporadic female patients had received different tentative diagnoses based on clinical assessments alone. Sequential observations of quantitative parameters (such as the time taken to run a fixed distance) were found to be useful clinical indicators for prognosis. Intellectual problems might modify the impression of physical ability in patients presenting at a young age. Histopathological assessment was accurate for DMD but differentiation between BMD and other disorders was more difficult, as was the identification of manifesting carriers. Our data on a small number of women with symptoms of muscle disease indicate that abnormal patterns of dystrophin labelling on sections may be an effective way of differentiating between female patients with a form of limb girdle dystrophy and those carrying a defective Xp21 gene. Dystrophin gene analysis detects deletions/duplications in 50 to 90% of male patients and is the most effective non-invasive technique for diagnosis. Quantitative Western blotting, however, would differentiate between all Xp21 and non-Xp21 male patients. In this study we found a clear relationship between increased dystrophin abundance (determined by densitometric analysis of blots) and clinical condition, with a correlation between dystrophin abundance and the age at loss of independent mobility among boys with DMD and intermediate D/BMD. This indicates that blotting is the most sensitive and accurate technique for diagnosis and prognosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8411069      PMCID: PMC1016531          DOI: 10.1136/jmg.30.9.745

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  41 in total

Review 1.  Genetic and clinical correlations of Xp21 muscular dystrophy.

Authors:  K M Bushby
Journal:  J Inherit Metab Dis       Date:  1992       Impact factor: 4.982

2.  Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis.

Authors:  R Gold; W Kress; B Meurers; G Meng; H Reichmann; C R Müller
Journal:  Muscle Nerve       Date:  1992-02       Impact factor: 3.217

3.  In vitro digestion of dystrophin by calcium-dependent proteases, calpains I and II.

Authors:  P Cottin; S Poussard; D Mornet; J J Brustis; M Mohammadpour; J Leger; A Ducastaing
Journal:  Biochimie       Date:  1992-06       Impact factor: 4.079

4.  Becker muscular dystrophy: demonstration of the carrier status of a female by immunoblotting and immunostaining.

Authors:  M P Chevron; S Tuffery; B Echenne; J Demaille; M Claustres
Journal:  Neuromuscul Disord       Date:  1992       Impact factor: 4.296

5.  Investigation of a female manifesting Becker muscular dystrophy.

Authors:  I A Glass; L V Nicholson; E Watkiss; M A Johnson; R G Roberts; S Abbs; S Brittain-Jones; H G Boddie
Journal:  J Med Genet       Date:  1992-08       Impact factor: 6.318

6.  Dystrophin or a "related protein" in Duchenne muscular dystrophy?

Authors:  L V Nicholson; M A Johnson; K Davison; E O'Donnell; G Falkous; M Barron; J B Harris
Journal:  Acta Neurol Scand       Date:  1992-07       Impact factor: 3.209

7.  Dystrophin abnormalities in polymyositis and dermatomyositis.

Authors:  C A Sewry; A Clerk; J Z Heckmatt; T Vyse; V Dubowitz; P N Strong
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

8.  Becker muscular dystrophy or spinal muscular atrophy?--Dystrophin studies resolve conflicting results of electromyography and muscle biopsy.

Authors:  T D McDonald; R Medori; D S Younger; H W Chang; C Minetti; A Uncini; E Bonilla; A P Hays; R E Lovelace
Journal:  Neuromuscul Disord       Date:  1991       Impact factor: 4.296

9.  Variable dystrophin expression in different muscles of a Duchenne muscular dystrophy carrier.

Authors:  F Muntoni; A Mateddu; M G Marrosu; M Cau; R Congiu; M A Melis; A Cao; C Cianchetti
Journal:  Clin Genet       Date:  1992-07       Impact factor: 4.438

10.  Prevalence of dystrophin-positive fibers in 85 Duchenne muscular dystrophy patients.

Authors:  M Fanin; G A Danieli; L Vitiello; L Senter; C Angelini
Journal:  Neuromuscul Disord       Date:  1992       Impact factor: 4.296

View more
  8 in total

Review 1.  What is the level of dystrophin expression required for effective therapy of Duchenne muscular dystrophy?

Authors:  Dominic J Wells
Journal:  J Muscle Res Cell Motil       Date:  2019-07-09       Impact factor: 2.698

2.  Validation of DE50-MD dogs as a model for the brain phenotype of Duchenne muscular dystrophy.

Authors:  Abbe H Crawford; John C W Hildyard; Sophie A M Rushing; Dominic J Wells; Maria Diez-Leon; Richard J Piercy
Journal:  Dis Model Mech       Date:  2022-03-02       Impact factor: 5.758

3.  Duchenne muscular dystrophy: negative electroretinograms and normal dark adaptation. Reappraisal of assignment of X linked incomplete congenital stationary night blindness.

Authors:  H Jensen; M Warburg; O Sjö; M Schwartz
Journal:  J Med Genet       Date:  1995-05       Impact factor: 6.318

Review 4.  Dilated cardiomyopathy and the dystrophin gene: an illustrated review.

Authors:  A Oldfors; B O Eriksson; M Kyllerman; T Martinsson; J Wahlström
Journal:  Br Heart J       Date:  1994-10

5.  Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An Interview.

Authors:  Dongsheng Duan
Journal:  Hum Gene Ther Clin Dev       Date:  2016-03       Impact factor: 5.032

6.  From proteins to genes: immunoanalysis in the diagnosis of muscular dystrophies.

Authors:  Rita Barresi
Journal:  Skelet Muscle       Date:  2011-06-24       Impact factor: 4.912

7.  Induction of revertant fibres in the mdx mouse using antisense oligonucleotides.

Authors:  Abbie M Fall; Russell Johnsen; Kaite Honeyman; Pat Iversen; Susan Fletcher; Stephen D Wilton
Journal:  Genet Vaccines Ther       Date:  2006-05-24

8.  Nifedipine treatment reduces resting calcium concentration, oxidative and apoptotic gene expression, and improves muscle function in dystrophic mdx mice.

Authors:  Francisco Altamirano; Denisse Valladares; Carlos Henríquez-Olguín; Mariana Casas; Jose R López; Paul D Allen; Enrique Jaimovich
Journal:  PLoS One       Date:  2013-12-09       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.